BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Motilal Oswal maintains buy on Torrent Pharma
Outperformance has been led by strong growth in exports. Stock trades at 15-times FY15 earnings per share and 13-times FY16 EPS. Net profit growth is faster than ebitda mainly due to lower than expected tax expenses. Growth in domestic formulations business was in-line. Target Rs 555.